RSV 604

Drug Profile

RSV 604

Alternative Names: A-60444; RSV-604

Latest Information Update: 22 Jul 2015

Price : $50

At a glance

  • Originator Arrow Therapeutics
  • Developer Arrow Therapeutics; Novartis
  • Class Antivirals; Benzodiazepinones; Phenylurea compounds; Small molecules
  • Mechanism of Action Nucleocapsid protein inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 16 Nov 2010 RSV 604 is still in active development
  • 02 Oct 2008 Preclinical trials in Respiratory syncytial virus infections (in infants) in United Kingdom (PO)
  • 31 Oct 2006 Phase-I clinical trials in Respiratory syncytial virus infections in volunteers United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top